LU91326I9 - - Google Patents

Info

Publication number
LU91326I9
LU91326I9 LU91326C LU91326C LU91326I9 LU 91326 I9 LU91326 I9 LU 91326I9 LU 91326 C LU91326 C LU 91326C LU 91326 C LU91326 C LU 91326C LU 91326 I9 LU91326 I9 LU 91326I9
Authority
LU
Luxembourg
Application number
LU91326C
Other languages
French (fr)
Other versions
LU91326I2 (fr
Inventor
David B Volkin
Henryk Mach
Li Shi
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26824774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91326(I9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of LU91326I2 publication Critical patent/LU91326I2/fr
Publication of LU91326I9 publication Critical patent/LU91326I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LU91326C 1999-03-26 2007-03-13 Vaccin papillomavirus humain Ä6,11,16,18Ü(recombinant, adsorbé) LU91326I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12652899P 1999-03-26 1999-03-26
US09/524,624 US6245568B1 (en) 1999-03-26 2000-03-13 Human papilloma virus vaccine with disassembled and reassembled virus-like particles
PCT/US2000/007595 WO2000057906A1 (en) 1999-03-26 2000-03-22 Human papillomavirus vaccine with disassembled and reassembled virus-like particles

Publications (2)

Publication Number Publication Date
LU91326I2 LU91326I2 (fr) 2007-05-14
LU91326I9 true LU91326I9 (https=) 2018-12-31

Family

ID=26824774

Family Applications (3)

Application Number Title Priority Date Filing Date
LU91326C LU91326I2 (fr) 1999-03-26 2007-03-13 Vaccin papillomavirus humain Ä6,11,16,18Ü(recombinant, adsorbé)
LU91328C LU91328I2 (fr) 1999-03-26 2007-03-13 Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé)
LU91327C LU91327I2 (fr) 1999-03-26 2007-03-13 Vaccin papillomavirus humain Ätypes 56,11,16,18Ü(recombinant, adsorbé)

Family Applications After (2)

Application Number Title Priority Date Filing Date
LU91328C LU91328I2 (fr) 1999-03-26 2007-03-13 Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé)
LU91327C LU91327I2 (fr) 1999-03-26 2007-03-13 Vaccin papillomavirus humain Ätypes 56,11,16,18Ü(recombinant, adsorbé)

Country Status (19)

Country Link
US (2) US6245568B1 (https=)
EP (1) EP1165126B1 (https=)
JP (1) JP4594534B2 (https=)
KR (1) KR20020013516A (https=)
AR (1) AR023166A1 (https=)
AT (1) ATE339222T1 (https=)
AU (1) AU778937B2 (https=)
CA (1) CA2368391C (https=)
CY (4) CY1105779T1 (https=)
DE (4) DE122007000032I1 (https=)
DK (1) DK1165126T3 (https=)
ES (1) ES2270822T3 (https=)
FR (1) FR07C0026I2 (https=)
LT (1) LTC1165126I2 (https=)
LU (3) LU91326I2 (https=)
NL (3) NL300269I2 (https=)
PT (1) PT1165126E (https=)
SI (1) SI1165126T1 (https=)
WO (1) WO2000057906A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962777B1 (en) * 1997-09-05 2005-11-08 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
US7351533B2 (en) 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
CA2875298A1 (en) * 1999-12-09 2001-06-14 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps)
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
CA2452720C (en) * 2001-07-26 2012-04-17 Chiron S.R.L. Vaccines comprising aluminium adjuvants and histidine
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
US20060073530A1 (en) * 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2003068163A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DE10237639A1 (de) * 2002-08-13 2004-02-26 Martin-Luther-Universität Halle-Wittenberg Verfahren zur Herstellung von virusanalogen Partikeln durch in vitro-Assemblierung von Kapsomeren oder von Kapsomeren, an die biologisch aktive Makromoleküle gebunden sind, bei gleichzeitiger Verpackung der Makromoleküle
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
EP2395073B1 (en) 2002-11-01 2017-09-06 GlaxoSmithKline Biologicals S.A. Drying process
WO2004056389A1 (en) 2002-12-20 2004-07-08 Glaxosmithkline Biologicals Sa Hpv-16 and -18 l1 vlp vaccine
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US20080131928A1 (en) * 2004-07-01 2008-06-05 Hiroshi Handa Viral Particle-Like Construct and Method of Forming the Same Under Physiological Conditions
JP5312799B2 (ja) * 2005-01-25 2013-10-09 ファイザー アイルランド ファーマシューティカルズ 収集精密ろ過における剪断保護剤
EP1907537A4 (en) * 2005-07-14 2010-11-10 Mayo Foundation Paramyxoviridae VIRUS PREPARATIONS
JPWO2007020871A1 (ja) * 2005-08-12 2009-02-26 アステラス製薬株式会社 デプシペプチド含有注射液
US20080268000A1 (en) * 2005-09-01 2008-10-30 Jose Luis Nuno Ayala Vaccine Stabilising Formula with Live Antigens for Use in Mass Vaccination Systems
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8962262B2 (en) * 2006-05-11 2015-02-24 Arbor Vita Corporation Method of protein extraction from cells
US9207240B2 (en) * 2007-11-14 2015-12-08 Arbor Vita Corporation Method of efficient extraction of protein from cells
JP5313231B2 (ja) * 2008-03-31 2013-10-09 森永乳業株式会社 耐熱性を付与する薬剤及び組成物
BR112012004699B1 (pt) 2009-09-03 2019-10-15 Becton, Dickinson And Company Métodos, composições e kits para lise química direta
KR101594228B1 (ko) 2010-08-23 2016-02-15 와이어쓰 엘엘씨 네이세리아 메닌기티디스 ｒＬＰ２０８６ 항원의 안정한 제제
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MX359256B (es) 2012-03-09 2018-09-19 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
WO2013139744A1 (en) 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Method of vaccination against human papillomavirus
KR101559622B1 (ko) 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US20200010850A1 (en) 2017-02-17 2020-01-09 The USA, as represeented by the Secretary, Dept. of Health and Human Services Efficient cell free production of papillomavirus gene transfer vectors
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN110987571A (zh) * 2019-12-31 2020-04-10 广州金域医学检验中心有限公司 一种单克隆多聚体m蛋白解聚方法
CN111812313B (zh) * 2020-06-22 2021-10-08 北京生物制品研究所有限责任公司 铝佐剂吸附型新型冠状病毒灭活疫苗中抗原的解离方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034594A1 (en) * 1997-02-06 1998-08-13 Merck & Co., Inc. Thimerosal-free preservatives for vaccines
JP4598201B2 (ja) 1997-04-08 2010-12-15 メルク・シャープ・エンド・ドーム・コーポレイション 安定化ヒトパピローマウイルス製剤
AU755679B2 (en) 1997-07-03 2002-12-19 Medimmune, Llc Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture,and the use thereof as diagnostic, prophylactic or therapy

Also Published As

Publication number Publication date
LU91327I9 (https=) 2019-03-01
FR07C0026I1 (https=) 2007-04-27
WO2000057906A1 (en) 2000-10-05
CY2007010I2 (el) 2009-11-04
NL300269I1 (nl) 2007-05-01
DE122007000032I1 (de) 2007-08-09
DK1165126T3 (da) 2007-01-08
DE122007000034I1 (de) 2007-08-09
JP4594534B2 (ja) 2010-12-08
CY1105779T1 (el) 2010-07-28
SI1165126T1 (sl) 2006-12-31
LU91327I2 (fr) 2007-05-14
DE60030698T2 (de) 2007-07-19
DE60030698D1 (de) 2006-10-26
NL300269I2 (nl) 2008-07-01
ATE339222T1 (de) 2006-10-15
NL300268I1 (nl) 2007-05-01
FR07C0026I2 (fr) 2012-08-03
LU91328I9 (https=) 2019-03-01
LU91328I2 (fr) 2007-05-14
CY2007009I2 (el) 2010-07-28
AR023166A1 (es) 2002-09-04
EP1165126B1 (en) 2006-09-13
CA2368391C (en) 2011-06-07
CY2007009I1 (el) 2010-07-28
CY2007010I1 (el) 2009-11-04
LTPA2007002I1 (lt) 2020-03-25
US20010021385A1 (en) 2001-09-13
AU3909300A (en) 2000-10-16
LTC1165126I2 (lt) 2020-04-27
LU91326I2 (fr) 2007-05-14
JP2002540167A (ja) 2002-11-26
NL300270I1 (nl) 2007-05-01
EP1165126A1 (en) 2002-01-02
CY2007008I1 (el) 2009-11-04
PT1165126E (pt) 2006-12-29
DE122007000033I1 (de) 2007-08-09
KR20020013516A (ko) 2002-02-20
US6245568B1 (en) 2001-06-12
CA2368391A1 (en) 2000-10-05
AU778937B2 (en) 2004-12-23
CY2007008I2 (el) 2009-11-04
ES2270822T3 (es) 2007-04-16

Similar Documents

Publication Publication Date Title
BE2016C007I2 (https=)
BE2015C018I2 (https=)
BE2008C046I2 (https=)
BE1025464I2 (https=)
JP2002525132A5 (https=)
BRPI0017527B8 (https=)
JP2002501231A5 (https=)
BRPI0001672A2 (https=)
JP2002523143A5 (https=)
JP2002532329A5 (https=)
LU91327I9 (https=)
BRPI0001542A2 (https=)
JP2002525779A5 (https=)
JP2002519930A5 (https=)
BRPI0012675B8 (https=)
BRPI0017522A2 (https=)
HU0004673D0 (https=)
BRPI0303609A (https=)
BRPI9917761A2 (https=)
ECSDI990565S (https=)
IN190075B (https=)
CN3098953S (https=)
AU2000278349A8 (https=)
CN3098433S (https=)
CN3098432S (https=)